Peripapillary choroidal atrophy in sympathetic ophthalmia and management with triple-agent immunosuppression

Ocul Immunol Inflamm. 2003 Mar;11(1):61-5. doi: 10.1076/ocii.11.1.61.15581.

Abstract

Purpose: To describe the occurrence of peripapillary choroidal atrophy and experience with triple-agent immunosuppression in three cases of sympathetic ophthalmia.

Materials and methods: Retrospective chart review of three cases of sympathetic ophthalmia with peripapillary choroidal atrophy.

Results: Three patients with sympathetic ophthalmia were managed with steroid pulse therapy and triple-agent immunosuppression. All three patients subsequently developed peripapillary choroidal atrophy.

Conclusions: Peripapillary choroidal atrophy can occur in sympathetic ophthalmia and may indicate a severe form of inflammation which would benefit from triple-agent immunosuppression.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Atrophy
  • Azathioprine / therapeutic use
  • Child
  • Choroid / pathology*
  • Choroid Diseases / drug therapy*
  • Choroid Diseases / etiology*
  • Cyclosporine / therapeutic use
  • Drug Therapy, Combination
  • Glucocorticoids / therapeutic use
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Male
  • Methylprednisolone / therapeutic use
  • Ophthalmia, Sympathetic / complications*
  • Ophthalmia, Sympathetic / drug therapy*
  • Prednisone / therapeutic use
  • Retrospective Studies

Substances

  • Glucocorticoids
  • Immunosuppressive Agents
  • Cyclosporine
  • Azathioprine
  • Prednisone
  • Methylprednisolone